SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001516551-21-000009
Filing Date
2021-09-30
Accepted
2021-09-29 19:29:45
Documents
13
Period of Report
2021-09-29
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K skye-20210929.htm   iXBRL 8-K 35503
2 EX-99.1 skye-rdclosingpressrelease.htm EX-99.1 10195
  Complete submission text file 0001516551-21-000009.txt   177164

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT skye-20210929.xsd EX-101.SCH 1921
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT skye-20210929_lab.xml EX-101.LAB 22080
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT skye-20210929_pre.xml EX-101.PRE 11526
6 EXTRACTED XBRL INSTANCE DOCUMENT skye-20210929_htm.xml XML 10722
Mailing Address 11250 EL CAMINO REAL, SUITE 100 SAN DIEGO CA 92130
Business Address 11250 EL CAMINO REAL, SUITE 100 SAN DIEGO CA 92130 (858) 410-0266
Skye Bioscience, Inc. (Filer) CIK: 0001516551 (see all company filings)

IRS No.: 450692882 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-55136 | Film No.: 211293080
SIC: 2834 Pharmaceutical Preparations